公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2017 | Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review | Chen L.-T.; Oh D.-Y.; Ryu M.-H.; KUN-HUEI YEH ; Yeo W.; Carlesi R.; Cheng R.; Kim J.; Orlando M.; Kang Y.-K. | Cancer Research and Treatment | 54 | 43 | |
2011 | Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib | Faivre S.; Zappa M.; Vilgrain V.; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Im S.-A.; Kang Y.-K.; Bouattour M.; Dokmak S.; Dreyer C.; Sablin M.-P.; Serrate C.; ANN-LII CHENG ; Lanzalone S.; Lin X.; Lechuga M.J.; Raymond E. | Clinical Cancer Research | 72 | 67 | |
2019 | Corrigendum to “Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis” [J Hepatol 71 (2019) 543–552](S0168827819303009)(10.1016/j.jhep.2019.05.014) | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. | Journal of Hepatology | 1 | 9 | |
2020 | Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial | Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; CHIUN HSU | JAMA Oncology | 697 | 646 | |
2020 | Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies | Yen C.-J.; Kudo M.; Lim H.-Y.; CHIH-HUNG HSU ; Vogel A.; Brandi G.; Cheng R.; Nitu I.S.; Abada P.; Hsu Y.; Zhu A.X.; Kang Y.-K. | Liver Cancer | 12 | 10 | |
2009 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | ANN-LII CHENG ; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z. | The Lancet Oncology | 4852 | 4547 | |
2012 | Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial | ANN-LII CHENG ; Guan Z.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Yang T.-S.; Tak W.Y.; Pan H.; Yu S.; Xu J.; Fang F.; Zou J.; Lentini G.; Voliotis D.; Kang Y.-K. | European Journal of Cancer | 220 | 212 | |
2022 | Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study | Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. | Gastric Cancer | 7 | 7 | |
2020 | Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer | Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. | Gastric Cancer | 43 | 39 | |
2019 | First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma | Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN ; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. | Cancer Discovery | 154 | 136 | |
2015 | Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial | Cainap C.; Qin S.; Huang W.-T.; Chung I.J.; Pan H.; Cheng Y.; Kudo M.; Kang Y.-K.; PEI-JER CHEN ; Toh H.-C.; Gorbunova V.; Eskens F.A.L.M.; Qian J.; McKee M.D.; Ricker J.L.; Carlson D.M.; El-Nowiem S. | Journal of Clinical Oncology | 476 | 453 | |
2012 | Management of colon cancer: Resource-stratified guidelines from the Asian Oncology Summit 2012 | Ku G.; Tan I.B.; Yau T.; Boku N.; Laohavinij S.; ANN-LII CHENG ; Kang Y.-K.; de Lima Lopes G. | The Lancet Oncology | 66 | 61 | |
2013 | Management of gastric cancer in Asia: Resource-stratified guidelines | Shen L.; Shan Y.-S.; Hu H.-M.; Price T.J.; Sirohi B.; KUN-HUEI YEH ; Yang Y.-H.; Sano T.; Yang H.-K.; Zhang X.; Park S.R.; Fujii M.; Kang Y.-K.; Chen L.-T. | The Lancet Oncology | 403 | 263 | |
2019 | Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis | Yau T.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. | Journal of Hepatology | 168 | 154 | |
2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. | The Lancet | 1656 | 1458 | |
2017 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial | El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU ; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. | The Lancet | 3010 | 2816 | |
2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab | Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. | Gastric Cancer | 50 | 43 | |
2020 | A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data | Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH ; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. | Gastric Cancer | 138 | 130 | |
2020 | Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors | Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; CHIA-CHI LIN ; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. | Molecular Cancer Therapeutics | 16 | 14 | |
2020 | Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors | Desai J.; Deva S.; Lee J.S.; CHIA-CHI LIN ; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. | Journal for ImmunoTherapy of Cancer | 79 | 73 | |